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Abstract
Rabbit haemorrhagic disease virus (RHDV) is a calicivirus of the genus Lagovirus that causes rabbit haemorrhagic
disease (RHD) in adult European rabbits (Oryctolagus cuniculus). First described in China in 1984, the virus rapidly
spread worldwide and is nowadays considered as endemic in several countries. In Australia and New Zealand
where rabbits are pests, RHDV was purposely introduced for rabbit biocontrol. Factors that may have precipitated
RHD emergence remain unclear, but non-pathogenic strains seem to pre-date the appearance of the pathogenic
strains suggesting a key role for the comprehension of the virus origins. All pathogenic strains are classified within
one single serotype, but two subtypes are recognised, RHDV and RHDVa. RHD causes high mortality in both
domestic and wild adult animals, with individuals succumbing between 48-72 h post-infection. No other species
has been reported to be fatally susceptible to RHD. The disease is characterised by acute necrotising hepatitis, but
haemorrhages may also be found in other organs, in particular the lungs, heart, and kidneys due to disseminated
intravascular coagulation. Resistance to the disease might be explained in part by genetically determined absence
or weak expression of attachment factors, but humoral immunity is also important. Disease control in rabbitries
relies mainly on vaccination and biosecurity measures. Such measures are difficult to be implemented in wild
populations. More recent research has indicated that RHDV might be used as a molecular tool for therapeutic
applications. Although the study of RHDV and RHD has been hampered by the lack of an appropriate cell culture
system for the virus, several aspects of the replication, epizootology, epidemiology and evolution have been
disclosed. This review provides a broad coverage and description of the current knowledge on the disease and the
virus.
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1. Natural history
In the 1980s, the European rabbit populations were
devastated by a new viral disease characterised by being
extremely lethal and highly contagious in both domestic
and wild rabbits (Oryctolagus cuniculus). The first out-
break of this new disease, designated as rabbit haemor-
rhagic disease (RHD), was noticed in 1984 in the
Jiangsu Province of the People’s Republic of China
within a group of commercially-bred Angora rabbits
imported from Germany [1]. In less than a year, RHD
killed 140 million domestic rabbits in China and spread
over an area of 50 000 km
2 [1,2]. Korea was the next
country to report RHD outbreaks which were associated
with rabbit fur importation from China [3]. The disease
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in 1986 [4] from where it spread to the rest of Europe,
becoming endemic in several countries. In the Iberian
Peninsula, where European rabbits originated and where
they constitute a key species of the ecosystem [5], the
first outbreaks date back to 1988 for Spain [6] and to
1989 for Portugal [7] and caused severe reduction of wild
populations [8,9]. At the same time, domestic popula-
tions from several countries in North Africa experienced
RHD outbreaks [10]. In the Americas, the first outbreaks
were recorded in 1988 in Mexico following the importa-
tion of rabbit products from China [11]. Nevertheless,
Mexico is currently the only country that has managed to
successfully eradicate RHD with the last outbreak having
occurred in 1992 [11]. This successful eradication of the
disease might correlate with the absence of natural popu-
lations of wild European rabbits. North America recorded
the first outbreak only in 2000 and experienced a few
additional outbreaks since then [12]. As the virus spread
worldwide, naturally occurring RHD outbreaks were
reported in geographically distant regions, such as Cuba,
Uruguay and Reunion Island [13,14].
RHD causes important economic losses in the rabbit
meat and fur industry and has a significant negative eco-
logical impact among wild rabbit populations and indir-
ectly on its dependant predators [2,11,15,16]. In
Australia and New Zealand, where the rabbit is consid-
ered an important agricultural pest, as well as a major
threat to the endemic wildlife flora and fauna [17,18],
rabbit haemorrhagic disease virus (RHDV) was soon
considered as an agent for rabbit control [19]. In 1991,
a scientific research program was initiated in laboratory
under quarantine measures to assess the host specificity
and efficacy of the RHDV Czech reference strain (Czech
V351) as a biocontrol agent. After approval of the Aus-
tralian authorities, RHDV was released in the Wardang
Island in Spencer Gulf, South Australia. Despite the rig-
orous quarantine measures, in 1995 RHDV escaped
from the island, possibly transported by insects or air
currents and reached the mainland [20]. In less than
two years, it became established across southern Austra-
lia. The initial spread was estimated to be 50 km per
week. In some areas a reduction of more than 95% of
the wild rabbit populations was observed, particularly in
the more arid regions [21]. In New Zealand, after a
careful investigation on the benefits and risks of intro-
ducing RHDV, the government decided not to introduce
the virus [19]. The virus was later illegally introduced by
landholders [22]. Posterior characterisation of the New
Zealand virus showed it to be similar to the Czech V351
strain introduced in Australia suggesting that it was
imported from there [23].
Nowadays, RHDV outbreaks still occur on almost all
continents and cause significant mortality rates, being
endemic in most parts of Europe, Asia, and parts of
Africa, Australia and New Zealand. As a general trend,
it seems that in areas where the European rabbit is his-
torically present as wild populations, RHDV is also pre-
sent and endemic. In contrast, in regions where the
European rabbit is mainly present as a domestic or
industrial animal, the occurrence of RHDV (epidemics
or rare outbreaks) seems to be correlated with rabbit
colony number and density.
2. Aetiological agent
Early efforts to classify RHDV were erratic, mostly due
to its non-cultivable nature. Initially suspected to be a
picornavirus [24], a parvovirus [25] and a parvo-like
virus [2], it was finally assessed in the early 1990s as a
member of the Caliciviridae family [26-30].
The International Committee on Taxonomy of Viruses
(ICTV) recognises four genera in the Caliciviridae
family: Lagovirus, Vesivirus, Norovirus and Sapovirus.
Three more genera were recently proposed as part of
this family: Nabovirus or Becovirus [31], Recovirus [32]
and Valovirus [33], but are not yet recognised by the
ICTV. Caliciviruses infect ab r o a dr a n g eo fa n i m a l s ,
including humans, and cause a variety of diseases, such
as gastroenteritis by Norovirus and Sapovirus, haemor-
rhagic disease by Lagovirus, and vesicular lesions,
respiratory infections and reproductive failure by Vesi-
virus.T h eLagovirus genus comprises both RHDV and
European brown hare syndro m ev i r u s( E B H S V ) ,av i r u s
first detected in Sweden in the early 1980s prior to the
first RHDV outbreak [34] which affects hare species
(Lepus europaeus and Lepus timidus). European brown
hare syndrome (EBHS) is closely related to RHD with
regards to clinical signs, pathological and histopathologi-
cal alterations, mortality rates, virion morphology and
antigenicity, but cross-species infection and cross-spe-
cies protection could not be obtained in a reproducible
way. Despite the similarities, RHDV and EBHSV repre-
sent distinct agents, infecting different species although
causing similar diseases [35-40].
As in other caliciviruses, RHDV virions are small sized
(between 35-40 nm of diameter) and non-enveloped.
The capsid, which forms the protein layer that protects
the RNA molecule, is composed of 90 arch-like dimers
of the capsid protein which form 32 cup-shaped depres-
sions (calix in Latin for cup or chalice as the root for
t h ef a m i l yn a m eCaliciviridae) arranged in a T = 3 ico-
sahedral symmetry [41,42]. Each capsid monomer con-
sists of a shell (S) domain which is buried and
comprises the N-terminal connected by a hinge to the
protruding (P) domain that encompasses the C-terminal
region and is exposed on the surface [39-41,43-46]. The
P domain can be further subdivided into the subdo-
mains P1 (stem of arch) and P2 (top of arch) [47]. The
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the capsid, displays the greatest genetic variation. This
variation is probably, at least in part, due to selection
pressure because host antibodies recognise and target
regions located in this subdomain [43,44,48]. In order to
avoid this recognition and the inherent selective pres-
sure, these regions tend to evolve faster [49,50] which
results in an increase of the genetic variability and
hence, of the antigenic variation. In addition, in noro-
viruses, the P2 domain has been shown to contain the
carbohydrate-binding domain, contributing to several
more conserved amino acids [51-53]. By analogy, this
should also apply to RHDV.
Sporadically, in rabbits affected by subacute or chronic
forms of RHD with long clinical courses, it is possible to
detect a second type of virus particle, the RHDV core-
like particles (CLP), also referred to as smooth particles
or s-RHDV [35]. These particles are found in large
amounts in the liver and spleen [54] and present unique
characteristics when compared to RHDV particles: a
smooth surface due to the lack of the cup-shaped
depressions; a smaller diameter of 25-29 nm; a molecu-
lar weight of 28-30 kDa indicating that CLP correspond
to the N-terminus (the buried shell domain) of the cap-
sid; no haemagglutinating activity, most likely as the
result of the absence of the C-terminus, but presenting
reactivity with sera from RHDV convalescent rabbits
and monoclonal antibodies directed towards the N-
terminal part of the RHDV capsid [35,54-56]. CLP seem
to be associated with the appearance of specific anti-
RHDV IgM [54]. Indeed, these particles have been sug-
gested to result from the degradation of the RHDV-IgM
immune-complexes formed during the humoral
response [54]. Although defective gene expression has
been suggested to be at the genesis of CLP [55], recent
data indicate that CLP directly derive from intact virions
with dissociated protrusion [45].
RHDV virions contain the genomic RNA (gRNA) and
an additional RNA species with 2.2 kb designated subge-
nomic RNA (sgRNA), which is collinear with the 3’ end
of the genomic RNA [26,57]. Subgenomic RNA usually
contributes to the production of high levels of products
required during the intermediate and late stages of
infection (e.g. structural proteins) [58]. For RHDV, these
comprise the capsid protein and VP10 [59-61]. Both the
genomic and subgenomic RNA are polyadenylated at
the 3’ end and at their 5’ region they are covalently
linked through a Tyr-21 residue to the VPg (virus gen-
ome-linked) protein [62]. The genomic RNA consists of
a positive-sense single-stranded molecule of 7437
nucleotides consisting of two slightly overlapping open
reading frames (ORF): ORF1, comprising nucleotides 10
to 7044 and ORF2, comprising nucleotides 7025 to 7378
[26]. ORF1 encodes a large polyprotein of ca. 257 kDa
[26] which is cleaved into the mature non-structural
proteins and a major structural protein, the capsid pro-
tein, by post-translational proteolytic processing by a
virus-encoded trypsin-like cysteine protease (Figure 1)
[57,63-65]. Some of these proteins derive from larger
precursors that result from further post-translational
modifications of the precursor proteins [57,64]. The bio-
logical role of some of the non-structural proteins
encoded by the genome of caliciviruses has been eluci-
dated by relying on previous knowledge gathered from
Figure 1 Genomic organization of RHDV. The genome of RHDV is composed of two narrowly overlapping ORFs, ORF1 and ORF2. ORF1 codes
for a polyprotein that is cleaved by the virus-encoded trypsin-like cysteine protease (arrowheads) and originates the major structural protein for
the capsid (VP60) and the non-structural proteins p16, p23, helicase, p29, VPg, protease and RdRp. ORF2 codes for a minor structural protein,
VP10. A subgenomic mRNA encoding both the structural proteins VP60 and VP10 can also be found in viral particles. Both the genomic and
subgenomic RNA are polyadenylated at their 3’end and have the virus-encoded protein, VPg, covalently attached to their 5’ end.
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[26,64,65]. For RHDV, two proteins involved in the
replication of the viral RNA, a helicase and an RNA-
dependent RNA polymerase (RdRp), and a protease
responsible for the proteolytic processing of the large
polyprotein, have been characterised [63,66,67]. RdRp
has been shown to also catalyse VPg uridylation [62,68]
while a role in translation has been suggested for VPg
[e.g. [69]]. The function of the RHDV non-structural
proteins p16, p23 and p29 remains to be assessed.
VP10, a minor structural protein encoded by the 3’end
of gRNA and sgRNA in a different reading frame
(ORF2), was recently shown to increase the levels of
virus replication and to promote apoptosis [70]. In addi-
tion, its ability to downregulate the expression of VP60
was demonstrated [71]. Together, this suggests that
VP10 might regulate virus replication and virion release
from infected host cells [71].
3. Clinical signs and histopathological lesions
The incubation period of the disease ranges between 1
to 3 days and rabbits usually succumb within 12 h to 36
h after the onset of fever (> 40°C). Depending on the
clinical evolution of the disease, three different clinical
courses can occur [38,72]. In the peracute form, infected
animals show no clinical signs and die suddenly. Acute
infections are accompanied by anorexia, apathy and con-
gestion of the palpebral conjunctiva and neurologic
symptoms such as opisthotonos, excitement, paralysis
and ataxia may also be observed. There are occasionally
some respiratory signs (tracheitis, dyspnea and cyanosis)
and a foamy and bloody nasal discharge; lacrimation,
ocular haemorrhages and epistaxis can also occur. Suba-
cute forms of the disease present similar, but milder
clinical symptoms and most rabbits survive. Rabbits
experiencing subacute infections develop antibodies
against RHDV which confer protection upon re-infec-
tion [73]. In addition, it has been reported that during
an outbreak of RHD, a low percentage of rabbits may
experience a chronic form of the disease with symptoms
including a severe and generalised jaundice, anorexia
and lethargy [35]. These animals tend to die 1-2 weeks
later [54], but animals that overcome the disease present
a potent seroconversion [35]. Interestingly, this form of
the disease has been shown to be associated with the
presence of RHDV core-like particles [35,55].
The liver, lung and spleen are the primary target tis-
sues of RHDV. The major histopathological lesions
found at necropsy are acute hepatitis due to liver cell
loss as the result of RHDV-induced apoptosis, and sple-
nomegaly [74,75]. Haemorrhages and congestions can
be seen in several organs, particularly in the lungs, heart
and kidneys, as a result of a massive disseminated intra-
vascular coagulation (DIC) which is usually the cause of
death [76]. Depletion of both B and T lymphocytes in
the liver and the spleen accompanies the disease and
accounts for an impairment of the immune response
[72,77] and a fatal progression of the disease within 2-3
days. In contrast, resistant rabbits develop high titres of
IgM (and then of IgA and of IgG) already at day 3 pi,
thus presenting an effective humoral immune response
[54]. Table 1 presents a summary of the histopathologi-
cal alterations that can be observed upon RHDV
infection.
4. Epidemiology
The possible routes for transmission of the disease are
the oral, nasal, conjunctival and parenteral, as blood-
feeding insects have also been shown to be efficient
mechanical vectors [72,78]. Transmission of RHDV may
occur through direct contact with an infected animal,
since infected rabbits may shed viral particles in their
secretions and excretions [79], or indirectly by means of
fomites-contaminated food, bedding, water, clothing,
cages and equipment [19]-or vector-borne transmission
Table 1 Pathological and histopathological lesions
[16,77,222,241,243]
Organ Lesions
Liver Enlarged with marked lobular pattern, yellow-grey
colour, brittle, circumscribed infiltration with
granulocytes, degenerative alterations of
hepatocytes compatible with apoptosis (extensive
vacuolization, severe alterations in the
mitochondrial structure, karyopyknosis and
karyolysis) activation of Kupffer cells, leukopenia
Trachea Hyperaemia of mucous membrane, petechial or
diffuse haemorrhages, may be filled with bloody
foam
Lung Hyperaemia, pulmonary oedema, intra-alveolar and
perivascular haemorrhages, sometimes slight
catarrhal bronchiolitis, proliferation of lymphocytes
Kidneys Enlargement with spotted dark red coloration,
hyperaemia, haemorrhages within glomerular
loops and renal medulla, hyaline thrombi, dilated
tubuli, lymphocytic infiltration, degeneration of
tubular epithelium
Spleen Enlargement (splenomegaly), spotted dark red
colorations, hyperaemia, occasionally karyorrhexis
within follicles, hemosiderosis, leukopenia
Digestive tract Contents usually normal, occasional enteritis,
subserous haemorrhages
Chest and
abdominal cavity
Small amounts of serous, occasionally bloody
exudate, sometimes subserous haemorrhages
Muscles Anaemia in the area of the thighs, petechiae in
the heart muscle, focal necrosis in myocardium,
degenerative alterations, hemosiderosis
Central Nervous
System
Congestion of cortical vessels, dilated vessels in
the area of the pia mater of the cortex and
cerebellum, hyperaemia, small haemorrhages in
the cortex, occasionally non-purulent
encephalomyelitis with lymphocytic infiltration
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[78,80,81]]. The natural doors for viral entry have been
suggested to be located in the upper respiratory and
digestive tract [16,82]. In natural infections, the faecal-
oral route is considered the preferential mode of trans-
mission [10,11].
In the field, carcasses of RHDV-infected rabbits may
be a major source for viral spreading since the virus
seems to be highly resistant and stable when exposed to
harsh environmental conditions. Indeed, carcasses of
RHDV-infected rabbits exposed to environmental condi-
tions have been found to contain viable viral particles
for up to three months [83,84]. This ability is para-
mount for the epidemiology of RHD and supports the
importance of indirect routes in transmission. Environ-
mental factors have also been suggested to impact on
the effectiveness of RHD in rabbit populations [reviewed
in [20]]. Temperature and humidity seem to be the
most important climate variables. Indeed, in Australia,
mortality rates due to RHD are higher in arid and semi-
arid inland areas than in moist coastal regions experien-
cing milder temperatures and the disease becomes active
during the breeding season, peaks in early spring and is
absent in the summer [85]. Climate variables might con-
tribute to the geographic and seasonality observed for
the RHDV outbreaks by affecting the abundance and
activity of the vectors involved in RHDV transmission
[reviewed in [20]]. Other non-climatic factors have also
been suggested to contribute to the variable pattern of
the impact of RHD in rabbit populations such as the
timing of the breeding season, the presence of a related
and protective RHDV-like calicivirus in rabbit popula-
tions or the negative interaction of the myxomatosis
outbreaks in the populations [reviewed in [86]]. In addi-
tion, modelling studies indicated that population
dynamics and spatial structure may greatly influence
disease impact and host-virus co-evolution [87,88].
Caliciviruses occur in a wide range of animals apart
from rabbits, which include mustelids (minks and
skunks), reptiles, cattle, felids (cats and cheetahs), dogs,
humans, chimpanzees, pigs and sea mammals (sea lions,
seals, walrus, whales, and dolphins), but they are usually
restricted to their primary host and closely related spe-
cies [89]. Indeed, rabbits and hares are the only hosts
for the RHDV and EBHSV lagoviruses, respectively.
Other leporid species have been shown not to be sus-
ceptible to RHDV [11]. Additionally, several non-host
species from the Australian fauna, including domestic,
feral animals and wildlife, were assessed for susceptibil-
ity to RHDV. No viral replication could be detected
with an extensive panel of tests which included clinical
observations, pathology, electron microscopy, virology
and serology, reinforcing the idea that susceptibility to
RHDV is restricted to the European rabbit (Oryctolagus
cuniculus) [90]. Both subspecies of the European rabbit,
O. c. cuniculus and O. c. algirus, seem equally suscepti-
ble to RHDV [91]. Interestingly, antibodies against
RHDV had been found in animals that live in sympatry
with rabbit populations infected with RHDV [81,92,93]
and, more recently, RHDV RNA was isolated from sym-
patric wild micromammals opening the possibility of
other species being involved in the epidemiology of the
disease [94].
5. Virus life cycle
In adult rabbits, the targets of the initial stages of the
virus life cycle have been determined. Indeed, viral anti-
gens are detected in the liver within the first hours fol-
lowing infection with RHDV with viral replication
occurring in the cytoplasm of hepatocytes located
mostly in centriacinar areas [30,74,95-98]. The number
of infected hepatocytes clearly increases in the course of
the disease, reaching a maximum between 36-48 h
[95-97]. Detection of viral antigens in Kupfer cells has
also been reported [74,98] associated with viral replica-
tion [98]. Extrahepatic presence of the virus has also
been observed, but some discrepancies exist between
the different studies since different techniques had been
employed. Nevertheless, viral antigens have been
detected in the spleen, in particular in the macrophages
located in the red pulp [96-98], kidney [96], and alveolar
macrophages in the lungs. It has been suggested that
the presence of replicating virus in alveolar macro-
phages, which are in contact with the bloodstream,
might be important for initial virus dissemination, and
later when the virus reaches the liver, Kupfer cells may
be important for spreading the infection into other
organs [98].
In contrast, viral dissemination in young resistant rab-
bits is far unclear. Viral antigens have been detected in
hepatocytes from experimentally-infected 2-week old
r a b b i t s[ 9 9 ] ,b u tm o s ts t u d i e sw e r eo n l ya b l et od e t e c t
them in rabbits older than 4-weeks [96,100]. Viral anti-
gens were found to be scattered and present in only a
small percentage of cells. Nevertheless, this suggests that
some hepatocytes in young (resistant) rabbits are able to
support viral replication, but that major changes must
occur in the liver to support a full infectious process. In
addition, clearance of the virus seems to be extremely
rapid as no viral antigens were detected after day 4 pi
[100]. The presence of the virus in other organs has not
been fully assessed.
However, as with most caliciviruses, understanding the
interaction between RHDV and its host has been ham-
pered by the lack of a suitable in vitro culture system.
Consequently, studies on the pathogenesis of calici-
viruses have relied on the ability of the capsid protein to
self-assemble into virus-like particles (VLP) when
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tage of being morphologically and antigenically indistin-
guishable from native virions, despite being devoid of
viral RNA [59,101-105]. RHDV VLP strongly aggluti-
nated human adult erythrocytes as the result of binding
to glycolipid ligands present on the erythrocyte surfaces
[72]. These ligands must develop with age since VLP
did not agglutinate erythrocytes from human umbilical
cords or foetuses presenting no agglutination [106]. Sub-
sequent studies revealed that several caliciviruses use the
carbohydrate moiety of host-cell histo-blood group anti-
gens (HBGA) for attachment (e.g. ABH/O and Lewis
antigens) initiating their replication cycle (Figure 2)
[82,107-115]. Histo-blood group antigens are complex
glycans either attached to proteins or lipids present on
the surface of epithelial cells and erythrocytes, either as
free oligosaccharides in biological fluids (milk, saliva,
blood and intestinal contents). HBGA are formed by the
sequential addition of monosaccharides to an oligosac-
charide precursor chain attached to the cell glycans.
This process, designated glycosylation, is catalysed by
glycosyltransferase enzymes with specific substrate affi-
nity and by a defined linkage [116]. Several genes
encode the glycosyltransferases resulting in ABO, Lewis
and secretor polymorphic phenotypes (Figure 3).
RHDV was shown to bind to the HBGA H type 2, A
type 2 and B type 2 oligosaccharides [82,117]. These
structures were shown to be present on the surface of
the epithelial cells of the upper respiratory and digestive
tracts that the virus first encounters when infecting the
host and therefore where doors for virus entry are most
likely located [16,82]. Synthesis of H type 2 requires the
Figure 2 The replication cycle of caliciviruses. After attachment to the cellular receptor, the virion is internalised into the cell (step 1).
Uncoating of the viral genome (step 2) is followed by translation of the polyprotein precursor (step 3) and co-translational processing releasing
the non-structural proteins (step 4). These proteins assemble in a replication complex (step 5) that synthesises the antigenomic RNA (step 6),
being itself used as a template for synthesis of the genomic RNA (step 7). The newly synthesized genomic RNA is translated as a polyprotein
precursor (step 3) or is used for packaging in the assembled viral protein core (step 10). The antigenomic RNA is also the template for synthesis
of subgenomic RNA (step 8). The subgenomic RNA is translated as structural proteins, VP60 and VP10 (step 9) and in lagoviruses, VP60 is also
released from the polyprotein precursor after processing by the viral protease. At a still not defined time in the virus life cycle, assembly of the
structural proteins as well as packaging of the genomic RNA occurs (step 10), followed by release of the mature virion from the cell (step 11).
Reprinted from Antiviral Research, 87, Rohayem J, Bergmann M, Gebhardt J, Gould E, Tucker P, Mattevi A, Unge T, Hilgenfeld R, Neyts J, Antiviral
strategies to control calicivirus infections, 167, 2010, with permission from Elsevier.
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tope [118], in a1,2 linkage to a precursor. This reaction
is catalysed by an a1,2-fucosyltransferase which in rab-
bits is encoded by three functional genes, Fut1, Fut2
and Sec1 that have undergone multiple events of gene
conversion during evolution [119]. Synthesis of the A
and B type 2 antigens involves the addition of either a
N-acetylgalactosamine or a galactose residue in a1,3
linkage to the H type 2 trisaccharide in a reaction cata-
lysed by an a1,3-N-acetylgalactosaminyltransferase or an
a1,3-galactosyltransferase (A or B transferases), respec-
tively. In rabbits, the ABO b l o o dg r o u pl o c u si sl a r g e l y
unresolved, but preliminary data suggest that at least 6
Abo genes exist in the genome, arranged in tandem (K
Nyström and J Le Pendu, personal communication).
Following the attachment of RHDV to the cell surface,
internalisation, by an unknown mechanism, and desen-
capsidation occur, leading to the release of the viral gen-
ome into the cytoplasm. The virus life cycle then
proceeds to the translation of the polyprotein precursor
encoded by the ORF1 of the viral genome through
interaction with the host cellular machinery. The gRNA
and the sgRNA covalently-linked VPg uses the cellular
translation machinery, positioning the ribosome at the
initiation codon AUG without ribosome scanning and
initiating translation [69,120]. Post-translational proteoly-
tic processing by the viral gRNA encoded protease
cleaves the polyprotein precursor into the mature non-
structural proteins and, in RHDV, into the capsid protein
VP60 [57]. The non-structural proteins, helicase and
RdRp, then form a replication complex synthesising a
complementary negative-s e n s eR N Af r o mt h eg e n o m i c
RNA which is used as a template for the synthesis of
gRNA and the sgRNA [reviewed in [121]]. The resulting
RNA can either be de novo translated or packaged into
viral particles that will be released from the infected cell.
The mechanism used by RHDV for dissemination of the
viral progeny is still unclear, but the ability of VP10 to
induce apoptosis may suggest a role in programmed cell
death in virion release and dissemination [70,95].
Translation of the RHDV ORF2 produces VP10
through a unique mechanism of reinitiation after
Figure 3 Schematic biosynthesis of the HBGA ABH and Lewis. Several transferase enzymes (boxed) are involved in the addition of relevant
monosaccharides (in bold) to synthesise the ABH and Lewis ligands in a variety of tissues. Gal, Galactose; Glc, Glucose; GalNAc, N-
Acetylgalactosamine; GlcNAc, N-Acetylglucosamine; Fuc, Fucose. With kind permission from Springer Science + Business Media: Glycoconjugate
journal, Norwalk virus-like particles bind specifically to A, H and difucosylated Lewis but not to B histo-blood group active glycosphingolipids, 26
(9), 2009, 1172, Nilsson J, Rydell GE, Le Pendu J, Larson G, Figure 1 (the figure includes minor alterations).
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protein [122]. This mechanism, although not fully
understood, is dependent on the RNA sequence located
upstream of the start/stop site, designated TURBS (ter-
mination upstream ribosomal binding site), but it is
independent on the presence of the AUG initiation
codon. Two critical motifs for VP10 expression have
been identified within TURBS: motif 1, which is highly
conserved among caliciviruses and shows complemen-
tarity with a short sequence in the 18S rRNA thus sug-
gesting an interaction between the viral RNA and the
ribosomal 18S rRNA, and motif 2, which is believed to
be involved in the correct positioning of the ribosome at
the translational start site [122,123].
6. Mechanisms of resistance to RHD
The lack of a cell culture system has been hampering
the study of RHDV pathogenesis and, as a consequence,
the mechanisms of resistance to the disease. The indir-
ect strategies that have been employed for the study of
the pathogenesis of RHDV allowed the identification of
the HBGA H type 2 as an attachment factor for RHDV
[82]. In humans, identification of alleles at the ABO,
FUT2 and FUT3 loci that generate failure to express
antigens recognised by different human Norovirus
strains and that confer resistance to infection led to the
search of such alleles in the a1,2-fucosyltransferase
genes in adult rabbits [124]. This represented the first
s t u d yo nt h eg e n e t i cm e c h a n i sms underlying resistance
to RHDV. A link between a rabbit allele at the a1,2-
fucosyltransferase gene Sec1, that also intervenes in the
H type 2 synthesis, and survival to a devastating RHDV
outbreak was demonstrated [124]. This Sec1 allele
encoded a weakly functional a1,2-fucosyltransferase, but
was always found associated with Fut2 alleles coding for
active enzymes that could compensate for the inability
of Sec1 to synthesise H type 2. The authors hypothe-
sised that this Sec1 allele was probably associated with a
mutation located in the regulatory region of Fut2 which
had compromised the Fut2 enzymes and, therefore, the
synthesis of the virus’ ligand. This result suggests that
allelic variation in the a1,2-fucosyltransferase gene
a p p e a r st oh a v eas i g n i f i c a n tr o l ei nr e s i s t a n c et o
RHDV. More recently, experimental challenge experi-
ments indicated that at low virus titres, adult rabbits
expressing low amounts of the HBGA ligands were less
susceptible to the disease than animals expressing high
amounts, although all animals were infected [117].
One striking characteristic of the pathogenesis is that
of resistance of young rabbits less than 2 months of age
to RHD [72]. Indeed, kittens less than 3 weeks old are
fully resistant, but when infected at an age of 4 weeks or
older the mortality rates increase to reach, at about 9
weeks old, the rates observed for adult individuals [10].
Thus, the mechanisms of resistance to RHDV have also
been studied in light of the differences observed
between adult and young rabbits. Interestingly, in
young-resistant rabbits the attachment factor H type 2
has been shown to be weakly expressed on the epithelial
cells of the upper respiratory and digestive tracts, where
primary infection by the virus is believed to occur
[82,106], which could explain their resistance to infec-
tion. Nevertheless, the reasons behind this differential
expression have not yet been disclosed and the picture
seems to be far more complicated. Indeed, and despite
compelling evidence that supports a role of carbohy-
drates in facilitating infection by RHDV in epithelial
cells of the upper respiratory and digestive tracts, other
attachment factors or receptors must be playing a role
at the epithelial level since low expression of the carbo-
hydrate receptor at the doors of entry confers only par-
tial protection against infection [117]. In addition,
hepatocytes, the main cellular target for viral replication,
have been shown not to express HBGA [82] and, in
young rabbits, infection is accompanied by hepatic
lesions due to virus replication as in adult individuals,
although they tend to be more severe in 4 week old
than in 2 week old rabbits [96,99,100,125,126]. This
indicates the existence of at least additional hepatic cel-
lular receptor(s) and that the genetic basis for the resis-
tance mechanisms goes beyond the attachment of the
virus to host cells through histo-blood group antigens.
Immune response related-genes, either of the innate or
the adaptive responses, are obvious candidate genes to
be involved in the resistance mechanisms to RHDV and
should deserve attention in future studies.
Differences in the innate immune response between
RHDV-infected adult and young rabbits have also been
observed [96,99,125-127]. Heterophils seem to be the
predominant type of leukocyte in the liver inflammatory
infiltrates in adult rabbits and are in close proximity
with damaged hepatocytes probably being involved in
the clearance of the dead cells. At variance, in young
rabbits, this infiltrate is composed mostly by lympho-
cytes associated with undamaged and possibly antigen-
presenting hepatocytes [127] and which are likely to
mount a more effective and specific immune response
than heterophils. In addition, in young rabbits only a
small fraction of hepatocytes supports viral replication
indicating that structural and functional changes have to
occur in the liver to support RHDV replication
[10,96,126].
Development of enzyme-linked immunosorbent assays
(ELISA) for the diagnosis of RHD [29,35] allowed an
early determination of the importance of humoral
immunity in the course of the disease. Indeed, animals
experiencing subacute forms of RHDV that survived
infection and that were later resistant upon re-exposure
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conversion [35,72,128,129]. A correlation between
cELISA titres and protection has been established which
is important for determination of the applicability of vac-
cination and to assess the current status of the disease
[54,128,130,131]. Recovering rabbits present IgM titres
that quickly reach a maximum within 2 weeks and then
sharply decrease. IgA titres are more prolonged in time,
but they also face a decrease. In contrast, IgG slowly
increase and are able to persist for months. With regards
to IgA, this suggests a mucosal response [128]. Passive
immunization (serotherapy) was also shown to be effec-
tive in stopping RHD in a rabbit farm hit by an outbreak
[132], demonstrating the importance of humoral immu-
nity in protection against RHD. In young rabbits, resis-
tance has also been associated with the presence of
maternal antibodies which are maintained during the
period of life when they are considered RHD-resistant
[128]. These are exclusively IgG acquired through the
placenta in the last days of pregnancy and show a decline
with age and body weight [19]. Additionally, if young rab-
bits are infected in their early life, they will become resis-
tant when adult, suggesting that their immune system is
capable of recognising the virus and producing an effec-
tive immune response that will confer long-term protec-
tion [133]. Therefore, humoral immunity clearly provides
protection against RHDV when present [28,103].
7. Genetic diversity/RHDV evolution
7.1. Pathogenic RHDV
The origin and evolution of RHDV are not well under-
stood. Although first reported in China in Angora rab-
bits imported from Germany, it was not clear if rabbits
were already infected with RHDV when they arrived in
China, since the disease might have been previously
observed in Germany [73], or if they became infected
later in China. The idea of RHDV being of Chinese ori-
gin has been challenged by several studies [50,134-136].
Indeed, these studies have shown that the pathogenic
form of RHDV originated before 1984 [50,134,136] and
that the Chinese strain isolated in 1984 had its origin in
European isolates [135]. In light of these results, it
seems that RHDV had its origins in Europe and that it
had been circulating for some time, but that mortalities
went unnoticed. Some hypotheses have been put for-
ward regarding how RHDV originated. One of them, the
transmission of the European brown hare syndrome
virus to the European rabbit [137] has been discarded
since EBHSV does not infect European rabbits. Other
hypotheses propose that a virus from another species
jumped to the rabbit where it became pathogenic [138],
but the presently favoured hypothesis would be the
change of a non-pathogenic virus closely related to
RHDV and that rendered it pathogenic (see below).
Identifying novel features in the genome of RHDV
m i g h tg i v es o m ei n d i c a t i o n so nt h eo r i g i no ft h ev i r u s
and its virulence. The first complete genome sequence
of RHDV was obtained in 1991 by Meyers et al. [26].
The characterisation of the genetic diversity was
initiated by sequencing and comparing partial sequences
of a few European isolates [139-141]. The isolates were
found to be highly similar and closely related.
Later, in an attempt to characterise the relation
between EBHSV and RHDV, Wirblich et al. presented
evidence that the N terminal portion of the capsid was
highly conserved while the highest degree of variability
was located in the C terminal half [39]. Indeed, while
for the N-terminus homology between caliciviruses is
~80%, no strict conservation was observed for the C-ter-
minus. In RHDV, this highly variable portion seems to
correspond to the C and E domains as defined by Neill
[47], where the majority of the differences between cali-
civirus isolates have been detected and where the main
antigenic determinants have been found to be located
[43,44,47,142-144]. These domains were predicted to be
located at the capsid surface [46] and therefore more
variable as a result of the strong selective pressure due
to exposure to the host immune system.
In 1997, the first phylogenetic analysis of RHDV iso-
lates with different geographic locations and spanning
the years from 1987 to 1995 was performed [137]. Inclu-
sion of all the available information identified three
major branches and supported the high degree of
homology between samples, as previously reported, but
also showed that RHDV strains clustered according to
the year of isolation and not according to their geo-
graphic location. Le Gall et al. found the same pattern
among French isolates, and further assigned the isolates
into three chronologically established genogroups, G1,
G2 and G3 [145]. Later, they observed that in France
G1 and G2 had disappeared and three new genogroups
had emerged: G4, having evolved from G3; G5, as a new
independent group, and G6 (Figure 4) [14]. Interestingly,
this genogroup G6 corresponded to the first antigenic
variant of RHDV previously detected by Capucci et al.
which they have designated as RHDVa [142]. This var-
iant, although having the same level of pathogenicity as
other RHDV isolates, presented a distinct antigenic pro-
file and characteristic genetic differences [142]. Indeed,
most of the amino acid variability found in RHDVa iso-
lates was clustered in the 5’ region of region E (spanning
the amino acid positions 344-370), no reactivity was
observed with the monoclonal antibody 1H8 that con-
fers protection to experimentally-infected rabbits, but
inoculation of vaccinated rabbits with RHDVa isolates
caused no death [142,146]. RHDVa appears as a subtype
of the RHDV wild-type (RHDVwt). These variants have
been isolated in several countries and were detected as
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[13,136,146-150]. In some areas, these variants seem to
be replacing the original strains [148].
In the Iberian Peninsula, only G1 strains have been
found, even among contemporary strains [91,134]. This
differs with the general pattern of RHDV evolution
observed in other European countries, but, overall, G1
strains seem to evolve following a temporal rather than
a geographic pattern as observed in the other gen-
ogroups [91]. This temporal structure is common in
RNA viruses and likely results from the strong selection
imposed by adaptive immune recognition by the host
[151]. This was confirmed for RHDV, where a few posi-
tively selected codons were detected located in the
major antigenic determinants of the capsid [49,50,134].
Interestingly, all the positively selected codons were
associated with potential N-glycosylation sites. Glycosy-
lation is known to play a role in the infectious process
in other non-enveloped viruses such as rotavirus and
Hepatitis E virus [152-155]. Positive selection recorded
at N-glycosylation sites in the capsid protein of RHDV
indicates that glycans might influence viral pathogeni-
city. This is further supported by the finding of non-
pathogenic RHDV-like strains which do lack some of
the positively selected N-glycosylation sites [49]
although it is not known at present if the capsid protein
from authentic virions is actually glycosylated.
Overall, with the exception of the RHDVa isolates, the
evolution of RHDV is associated with a high degree of
genetic homogeneity, with maximum nucleotide and
amino acid differences of 10% and 6%, respectively
[14,90,91,137,139-141,145,147,150,156-163], and mostly
located in the regions C and E. These differences are
much lower than those observed for other caliciviruses
(e.g. for Norovirus, amino acid differences can reach a
maximum of 61.4% while for Sapovirus they can reach
55%) [164,165]. This high homology may have resulted
from the rapid spread of a new virus, expanding into a
susceptible host population [139], but also from the fact
that RHDV is a newly emerging pathogen whose evolu-
tion started recently, at variance from that of Norovirus
and Sapovirus.
7.2. Non-pathogenic rabbit calicivirus
The emergence of RHDV from a pre-existing non-
pathogenic rabbit calicivirus that has mutated and
become pathogenic to rabbits has been hypothesised
[136,139,160,166-168]. The detection of antibodies spe-
cific to RHDV in rabbit sera collected before the first
RHDV outbreak, the identification of RHDV-seroposi-
tive rabbits where RHD was never recorded and the pre-
sence or persistence of viral RNA in populations where
no overt signs of disease could be observed, provided
compelling evidence for the pre-existence of a non-
pathogenic RHVD-like virus in European rabbit popula-
tions [29,128,160,169-179]. This non-pathogenic virus
would share antigenic properties with RHDV and circu-
lated asymptomatically amongst rabbit populations
before the first RHDV outbreak in China. Isolation of
several non-pathogenic rabbit caliciviruses related to
RHDV but with a tropism limited to the gut and no
obvious pathogenicity further substantiated this hypoth-
esis [160,166,168,176,180,181] and showed that the non-
pathogenic strains are still circulating. Protection to
RHD had been shown to be conferred by some of these
non-pathogenic strains which might provide an explana-
tion for the low level of RHD incidence in some regions
of Australia and Britain [166,168,169,171,173,179,
182-184]. More recently this hypothesis was confirmed
experimentally when Strive et al. showed that the non-
pathogenic Australian strain RCV-A1 is able to generate
an antibody response that cross-reacts to RHDV and
further protects animals from RHD, but not completely
and not from infection [184]. Other strains, however, do
not confer any kind of protection [181,185].
Understanding the evolutionary history and the origin
of RHDV will benefit from further studies of the non-
pathogenic strains. The isolation of non-pathogenic
Figure 4 Phylogenetic relationships between the RHDV
genogroups G1-G6 and the Italian non-pathogenic strain RCV.
The tree was obtained using the neighbour-joining method and
using nucleotide sequences from RHDV strains isolated worldwide.
Bootstrap values greater than 50% are presented at the nodes. RCV
was used as outgroup to root the tree. With kind permission from
Springer Science + Business Media: Archives of Virology,
Phylogenetic analysis of rabbit haemorrhagic disease virus in France
between 1993 and 2000, and the characterisation of RHDV antigenic
variants, 148(1), 2003, 72, Le Gall-Recule G, Zwingelstein F, Laurent S,
de Boisseson C, Portejoie Y, Rasschaert D, Figure 2 (the figure
includes minor alterations).
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between these strains and the pathogenic RHDV strains,
with the most important being, beside pathogenicity, tis-
sue tropism and capsid variability [160,166,168,176,180].
Interestingly, MRCV, a new variant of the non-patho-
genic rabbit calicivirus (RCV)-like group that was
recently characterised [180,186], displayed a pathogeni-
city of approximately 30% which is significant and in
contrast with reports from other non-pathogenic strains.
The viral RNA of this strain was detected in the liver
rather than in the intestine which seems to indicate that
the ability of a strain to cross the epithelia barrier and
reach other organs such as the liver is an important fea-
ture for the emergence of the pathogenic forms and
should be further explored. However, these results
should be considered with caution since experimental
reproduction of the disease failed, with only 2 out of the
14 inoculated rabbits presenting very mild symptoms.
Despite the accumulation of data, no mutations have
yet been attributed that would explain the switch from a
non-pathogenic to a pathogenic form. Recombination
within the RHDV genome is not uncommon [187,188]
and might have played a role in the origin of RHDV.
Indeed, the recombination event reported by Forrester
et al. [188] in the strain isolated in 1984 in China may
suggest that recombination was a common mechanism
a tt h et i m eo fe m e r g e n c eo ft h ep a t h o g e n i cf o r m s .
Nevertheless, not all pathogenic forms are direct descen-
dants of this strain [135] and despite the relatively high
frequency at which recombination occurs (4 out of 10),
it does not seem to be widespread in all RHDV lineages
[136]. This might be the result of an incomplete and
non-systematic sampling or of the scarcity of complete
genomic sequences.
Recently, novel phylogenetic analysis approaches were
used to assess the emergence of RHDV [50,134,136].
Although the results could have brought an insight into
the timing of the appearance of the non-pathogenic and
the pathogenic forms of the virus, the studies led to
incongruent results most likely as the result of the dif-
ferent capsid fragment lengths used in each study. This
poses the question if the capsid is indeed the best gene
for inferring RHDV history. While Kerr et al. could
establish the Time to Most Recent Common Ancestor
(TMRCA) between RHDV and the non-pathogenic
forms of < 550 years and of < 150 years for the patho-
genic forms [136], Kinnear and Linde set the existence
of the ancestor of RHDV-RCV later in the 1930s and of
the ancestor of the pathogenic RHDV strains between
1957-1976 [50]. Consistent with the findings of Kerr et
al., Alda et al. set the TMRCA for all the RHDV to
~1884 [134]. Nevertheless, and considering these esti-
mates, it is surprising that the disease had not been
reported earlier than 1984. This might suggest an
alternative scenario for the virus emergence where the
virus would have come from another species through a
species jump, that would have acted as a reservoir and
was not affected by RHDV [136]. This scenario, how-
ever, implies the existence of such a reservoir host in
which the virus was able to replicate. Viral RNA has
been recently detected and isolated in micromammals
living in sympatry with European rabbit populations
that could represent the unidentified reservoir [94], but
viral replication within these species could not be con-
firmed. Since these species might be important for virus
transmission and spread and perhaps represent the
“unknown” reservoir for when the virus seems to be
inactive, i.e. between outbreaks, this hypothesis should
be further explored.
8. Host-virus co-evolution
The virus-host dynamics result in a co-evolutionary pro-
cess between the host resistance mechanisms and the
virus escape mechanisms with attenuation of the virus
and/or increase in resistance of the host. Therefore, the
study of the host-virus co-evolutionary processes
requires the analysis of each element of this dynamical
pair simultaneously. Regarding the host, and in order to
identify signatures of selection due to infectious agents,
the natural history of this species should be considered.
The fossil record suggests that the European rabbit ori-
ginated in the Iberian Peninsula during the medium
Pleistocene [189-192] and two morphologically differen-
tiated subspecies have been distinguished: O. cuniculus
algirus and O. cuniculus cuniculus [193]. O. c. algirus
inhabits the southwestern Iberian Peninsula, while O. c.
cuniculus is present in the northeastern Iberian Penin-
sula. These two subspecies diverged ~1.8 Mya [reviewed
in [194]] and then, by a post-glaciation expansion from
the southwestern refugium to North and from the
Northeastern to South or West, a contact zone was
established. While the natural populations of O. c.
algirus remained confined to the southwest of the
Peninsula, the natural populations of O. c. cuniculus
later expanded its range north towards France, likely
after the last glacial peak [195], where they still remain
present. The expansion of these populations with suc-
cessive bottleneck events caused a significantly lower
genetic diversity of the wild French O. c. cuniculus
populations compared to the Iberian populations
[195-201]. The European rabbit gene pool has been
manipulated by man through a recent single domestica-
tion event of French origin, and therefore, all domestic
rabbits belong to the subspecies O. c. cuniculus
[reviewed in [201,202]]. Today, by man-mediated disper-
sal, the subspecies O. c. cuniculus can be found in Eur-
ope, Australia, New Zealand, North and South America,
and North Africa. The gene pool of the European rabbit
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these events and this might have also interfered with the
resistance mechanisms. Therefore, when studying the
co-evolution between the European rabbits and RHDV,
these events should be taken into account.
The introduction of myxoma virus in Australia was
soon followed by an increase in genetic resistance in
rabbits and the appearance of less virulent strains [203].
Recent field studies conducted in Australia suggest that
RHDV also has become less effective in keeping wild
rabbit numbers low and that in some populations rabbit
numbers are returning to the pre-RHDV levels [204].
Laboratory challenges have confirmed this scenario
when inoculation of rabbits from different Australian
populations with the original introduced strain (Czech
strain V351) failed to induce mortality or induced mor-
tality rates lower than that which was expected [205]. In
addition, in an Australian population, the frequency of
host resistant phenotypes, i.e., phenotypes that confer a
weak binding of the virus to the host HBGA that facili-
tate infection and thus provide protection to the host,
has significantly increased [117]. A similar co-adaptation
process seems to be occurring both in New Zealand
[92] and in rabbit populations from Europe [117].
Indeed, Nyström et al. found that in a French wild rab-
bit population recovering from a major RHDV outbreak
the frequency of resistant phenotypes increased among
the survivors [117]. As with the Australian population,
the resistant phenotypes are associated with weak viral
binding. This indicates that the virus has contributed to
select resistant hosts in accordance to the binding speci-
ficities of the circulating RHDV strains and gives further
support for a role of the HBGA in the virus epidemiol-
ogy and suggests that the virus is shaping the hosts’
HBGA diversity.
T h ev i r u sa l s os e e m st ob ee v o l v i n gt oo v e r c o m et h e
host resistance mechanisms since significant mortalities
are still observed in the field, at least in Australia. Evi-
dence for this comes from the fact that in comparative
trials in rabbits known to be resistant to infection with
Czech 351, modern field strains appeared more virulent
than the original released strain, suggesting they had
evolved to keep pace with changes in rabbit resistance
[205]. In addition, HBGA specificities of the strains that
e v o l v e di nF r a n c ef r o m1 9 8 8t o2 0 0 9p r o g r e s s i v e l y
shifted, allowing preferential recognition of subgroups of
animals that express distinct HBGA motifs, which sug-
gests an adaptation to the host genetic diversity [117].
9. Prevention, control and vaccination
In animals presenting subclinical or no clinical signs,
passively acquired immunity has been shown to act suc-
cessfully in emergency situations [132]. Indeed, this
therapy, which is achieved by inoculation with a
hyperimmune antiserum, confers short-term protection,
preventing death. Nevertheless, passive immunization is
ineffective on animals presenting clinical signs. Thus, as
yet, no cure is available for RHDV-dying rabbits. Pre-
vention and control of the disease through biosecurity
and immunoprophylactic measures such as vaccination
are, therefore, of utmost importance. Due to the lack of
a cell culture system for efficient virus propagation,
commercially available vaccines against RHDV are pro-
duced from tissue suspensions of experimentally
infected rabbits, followed by chemical inactivation of the
virus [132,177,206]. However, and to obviate the risks
inherent to the manufacturing and use of this kind of
vaccines (the use of infectious particles, the need for a
safe disposal of contaminant residues, social concerns
on animal welfare) the RHDV capsid protein has been
tested in various studies as a subunit vaccine against
RHD. Several heterologous expression systems or
recombinant animal viruses have been developed to pro-
duce recombinant versions of the VP60 protein. The
VP60 recombinant protein has been produced in Escher-
ichia coli [140]; insect cultured cells [59,101-104]; yeast
[207,208]; plants [209-213]; insect larvae [214] and
recombinant animal-derived viruses [215-219]. Most of
these systems were shown to be immunogenic and to
confer protection against lethal doses of RHDV by elicit-
ing a humoral response indicating that they are good
substitutes for the tissue vaccines. Features such as low
cost, high yields and ease of scaling up are amongst the
most important factors for their commercial viability.
Although commercially available vaccines have proven
effective in rabbitries, in wild rabbit populations vaccina-
tion campaigns are economically and logistically imprac-
ticable and their effects are considered insignificant
[220]. Indeed, administration to wild rabbits implies
capturing and handling of rabbits which by being a
stress factor might increase the mortality rates [221]. In
addition, this would need to be performed systematically
since induced-immunity lasts no longer than 1 year
[222] and efficacy has been shown to be dependent on
several physiological parameters of the individuals [223].
Therefore, alternative approaches are being explored to
overcome these limitations such as the development of
vaccines with the capacity for horizontal transmission to
ensure appropriate immunization of a relevant portion
of the population [219], vaccines that may be adminis-
tered by the oral or nasal routes [105,208,213,217,219,
224,225] or the construction of bivalent vaccines
[216,226]. Nevertheless, as yet, none of these vaccines
has been registered or is commercially available.
Biosecurity measures for control and prevention of
RHD, including surveillance, sanitation, disinfection and
quarantine, are of high importance to limit propagation
and to ensure prevention of the disease in particular in
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in wild rabbits and where eradication is not achievable,
these measures might prevent large-scale infection in
rabbitries. Thus, a careful and correct management of
the RHDV outbreaks is always dependent on the epide-
miological situation of the regions where they occur. In
addition, a continuous monitoring of the viral evolution
in the field is fundamental for the quick detection of
new genetic and antigenic variants which might be
determinant for the application of the most appropriate
measures.
10. Therapeutic applications of RHDV
More recently, RHDV VLP have been considered as a
mean for cancer and pathogen immunotherapies
[227-232]. The capsid protein of RHDV spontaneously
assembles into VLP which are morphologically and anti-
genically indistinguishable from native virions, but
devoid of the viral RNA [101]. By genetic engineering,
RHDV VLP have been shown to efficiently incorporate
antigens that might be presented to immune cells and
to elicit an adequate cell-mediated and humoral immune
response [228-232]. In addition, RHDV VLP have the
advantage of being easily produced and at low cost, and,
by deriving from a non-human virus, they are not sus-
ceptible to pre-existing neutralising antibodies [228],
thus providing a reliable molecular tool for therapeutic
applications.
RHDV has also been investigated for the study of
virally-induced acute liver failure (ALF) in humans
[233-239] as it fulfils several of the requirements to be a
good animal model [233]. ALF is a condition charac-
terised by severe liver injury, hepatic encephalopathy,
coagulopathy and multiorgan failure, with viral infec-
tions (e.g. hepatitis A, B and E) and drug use (e.g. para-
cetamol overdose) amongst the commonest causes
[240]. The hepatic lesions observed following infection
by RHDV [99] resemble those caused by ALF in
humans, but other physiologic, histological and bio-
chemical alterations are also shared. Indeed, the hemo-
dynamic changes, alterations in the intracranial pressure
and histological alterations such as apoptosis observed
in RHDV are common to ALF [74,233,241,242]. In addi-
tion, clinical symptoms such as prostration or convul-
sions observed on RHD are also observed in ALF [38].
RHDV has also been used for the study of therapeutic
approaches for ALF [236,238,239].
11. Conclusions
Despite the lack of an appropriate cell culture system,
some light has been shed on several aspects of RHDV
and RHD. Nevertheless, the host-parasite interactions
established between RHDV and the European rabbit are
still unclear. Indeed, the role of some of the proteins
encoded by RHDV is still unknown and the emergence
of RHDV as a pathogenic form has not yet been
resolved. In order to clarify these gaps, an effort should
be made in obtaining full genomic sequences, including
for non-pathogenic strains as these might contribute to
understand the pathogenesis of RHDV. As for the host,
and in particular as for key factors of susceptibility and
resistance, the rabbit genome project should be consid-
ered and used for the study of candidate genes. By using
temporal samples, i.e., samples of rabbits collected
before and after RHDV outbreaks, one might determine
those candidate genes. Further studies on immunity to
R H D Va n do nt h er e l a t e dn o n -pathogenic viruses are
also warranted for a better understanding of the host-
pathogen relationships. In addition, the study of the clo-
sely related EBHSV and its host, might contribute to the
understanding of the interplay between lagoviruses and
leporid species. The possibility that RHDV might be
used as a model for the study of other calicivirus infec-
tions, in particular in view of its non-pathogenicity for
humans, as well as for the development of anti-cancer
and pathogen therapies transforms it into a valuable
research molecular tool.
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